The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Use of arsenic trioxide (As2O3) in the treatment of patients with acute promyelocytic leukemia: The M. D. Anderson experience
Abstract
BACKGROUND: Approximately 20–30% of patients with acute promyelocytic leukemia (APL) who are treated with all‐trans retinoic acid (ATRA) and an anthracycline develop recurrent disease. It has been reported that arsenic trioxide (As 2 O 3) is effective in this setting. The authors report the experience of The M. D. Anderson Cancer Center with As 2 O 3 in the treatment of patients with recurrent APL. METHODS: Twelve patients who developed recurrent APL after treatment with ATRA were included. Patients received intravenous As 2 O 3 0.15 mg/kg per day until they achieved a complete remission (CR) or up to a maximum of 60 days. Their median age was 44 years (range, 26–72 years), and the median duration of first remission was 52 weeks (range, 23–292 weeks). RESULTS: All 12 patients achieved a CR. The median time to achieve CR was 52 days (range, 27–75 days). Seven of 10 evaluable patients achieved a molecular remission (i.e., polymerase chain reaction [PCR] analysis was negative for the gene encoding fusion of the nuclear receptor for retinoic acid to the PML gene at the time of CR; 70% of patients; 95% confidence interval, 0.35–0.93), and all other patients had negative PCR results after they received postremission therapy. All patients received subsequent therapy: Four patients received As 2 O 3 alone, six patients received As 2 O 3 with other chemotherapeutic agents, and two patients received idarubicin plus ATRA without As 2 O 3. Eight patients continued in CR after a median follow‐up of 24 months (range, 9–45 months). Side effects were mild, except for two patients who developed Grade 2 and 3 peripheral neuropathy, respectively; one of those patients required discontinuation of therapy. CONCLUSIONS: As 2 O 3 is effective and well tolerated therapy for patients with recurrent APL. Molecular remission may be achieved at the time of CR in the majority of patients, and remissions are durable. Cancer 2003;97:2218–24. © 2003 American Cancer Society. DOI 10.1002/cncr.11314
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia
Huang, M., Ye, Y., Chen, Sr., Chai, Jr., Lu, J., Zhoa, L., Gu, L., & Wang, Z. (1988) · Blood · doi:10.1182/blood.v72.2.567.567 · Cited by 2,445
Shen, Z.-X., Chen, G.-Q., Ni, J.-H., Li, X.-S., Xiong, S.-M., Qiu, Q.-Y., Zhu, J., Tang, W., Sun, G.-L., Yang, K.-Q., et al. (1997) · Blood · doi:10.1182/blood.v89.9.3354 · Cited by 1,428
Differentiation Therapy of Acute Promyelocytic Leukemia with Tretinoin (All-trans-Retinoic Acid)
Warrell, R. P., Frankel, S. R., Miller, W. H., Scheinberg, D. A., Itri, L. M., Hittelman, W. N., Vyas, R., Andreeff, M., Tafuri, A., Jakubowski, A., et al. (1991) · New England Journal of Medicine · doi:10.1056/nejm199105163242002 · Cited by 1,251
Complete Remission after Treatment of Acute Promyelocytic Leukemia with Arsenic Trioxide
Soignet, S. L., Maslak, P., Wang, Z.-G., Jhanwar, S., Calleja, E., Dardashti, L. J., Corso, D., DeBlasio, A., Gabrilove, J., Scheinberg, D. A., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391901 · Cited by 1,213
Chen, G., Zhu, J., Shi, X., Ni, J., Zhong, H., Si, G., Jin, X., Tang, W., Li, X., Xong, S., et al. (1996) · Blood · doi:10.1182/blood.v88.3.1052.1052 · Cited by 864
United States Multicenter Study of Arsenic Trioxide in Relapsed Acute Promyelocytic Leukemia
Soignet, S. L., Frankel, S. R., Douer, D., Tallman, M. S., Kantarjian, H., Calleja, E., Stone, R. M., Kalaycio, M., Scheinberg, D. A., Steinherz, P., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.18.3852 · Cited by 826
Self-citationWarrell, R. P., de The, H., Wang, Z.-Y., & Degos, L. (1993) · New England Journal of Medicine · doi:10.1056/nejm199307153290307 · Cited by 776
He, L.-Z., Figueiredo-Pontes, L. L., Rego, E. M., & Pandolfi, P. P. (2015) · Encyclopedia of Cancer · doi:10.1007/978-3-662-46875-3_63 · Cited by 766
Mandelli, F., Diverio, D., Avvisati, G., Luciano, A., Barbui, T., Bernasconi, C., Broccia, G., Cerri, R., Falda, M., Fioritoni, G., et al. (1997) · PubMed · doi:10.1182/blood.v90.3.1014 · Cited by 474
Chen, Z., Xue, Y., Zhang, R., Tao, R., Xia, X., Li, C., Wang, W., Zu, W., Yao, X., & Ling, B. (1991) · Blood · doi:10.1182/blood.v78.6.1413.1413 · Cited by 399
Cited by
Acute and chronic arsenic toxicity
Ratnaike, R. N. (2003) · Postgraduate Medical Journal · doi:10.1136/pmj.79.933.391 · Cited by 1,175
Arsenic degrades PML or PML–RARα through a SUMO-triggered RNF4/ubiquitin-mediated pathway
Lallemand-Breitenbach, V., Jeanne, M., Benhenda, S., Nasr, R., Lei, M., Peres, L., Zhou, J., Zhu, J., Raught, B., & de Thé, H. (2008) · Nature Cell Biology · doi:10.1038/ncb1717 · Cited by 734
Tallman, M. S. (2002) · Blood · doi:10.1182/blood-2002-02-0632 · Cited by 482
Keckesova, Z., Ylinen, L. M. J., & Towers, G. J. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0402474101 · Cited by 344
Zhang, T.-C. (2003) · Carcinogenesis · doi:10.1093/carcin/bgg141 · Cited by 142
Metadata
- Authors
- Lazo, G., Kantarjian, H., Estey, E., Thomas, D., O'Brien, S., & Cortes, J.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2003-04-17
- Volume
- 97
- Issue
- 9
- Pages
- 2218-2224
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W1692919389
- Cited by
- 494
- References
- 28
- FWCI
- 12.55
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Use of arsenic trioxide (As2O3) in the treatment of patients with acute promyelocytic leukemia: The M. D. Anderson experience. https://app.cochat.ai/papers/10.1002/cncr.11314
- The paper
- Lazo, G., Kantarjian, H., Estey, E., Thomas, D., O'Brien, S., & Cortes, J. (2003). Use of arsenic trioxide (As2O3) in the treatment of patients with acute promyelocytic leukemia: The M. D. Anderson experience. Cancer. https://doi.org/10.1002/cncr.11314
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
